title: Cytostatic murine B16 cell-pulsed dendritic cells induce effective protection against melanoma in mice.
abstract: BACKGROUND
  Peripheral blood mononuclear cells (PBMCs) present an antitumor activity in vitro on doxorubicin-resistant B16 melanoma (B16R) spheroids, but do not inhibit tumor growth in vivo. This study aimed to improve in vivo the antitumor immune response by using antigen presenting cells.
  
  
  METHODS
  After injection of B16R cells, mice received either tumor cell lysate-pulsed PBMCs, or naive or cytostatic tumor cell-pulsed bone marrow-derived dendritic cells (DCs). Tumor development and mouse survival were followed and spleen cell cytotoxic activity against B16R was estimated in vitro by Lactate dehydrogenase activity measurement.
  
  
  RESULTS
  The best results were obtained with peritumoral injections of cytostatic tumor cell-pulsed DCs which induced tumor regression, increased mouse survival and exhibited a higher splenocyte cytotoxic activity against B16R cells. When injected at a distant site, the efficacy was reduced. Furthermore, preventative injections of pulsed DCs induced protection of mice against B16R cells.
  
  
  CONCLUSIONS
  These results show the important role of cytostatic tumor cell-pulsed DCs in a specific antitumor immunity establishment. Consequently, they could be used combined with other treatments to improve clinical outcomes.
authors.affiliation: Laboratoire de Biologie Cellulaire and Moléculaire, EA 3796, U.F.R. des Sciences Exactes et Naturelles, Moulin de la Housse, BP 1039, 51687 Reims 2, France. deborah.joseph@univ-reims.fr
authors.forename: Debora
authors.initials: D
authors.lastname: Joseph-Pietras
authors.forename: Annie
authors.initials: A
authors.lastname: Carlier
authors.forename: Claudie
authors.initials: C
authors.lastname: Madoulet
authors.forename: Philippe
authors.initials: P
authors.lastname: Albert
mesh_terms: D000818:Animals; D048708:Cell Growth Processes / Q000276:immunology; D003713:Dendritic Cells / Q000276:immunology*; D005260:Female; D016219:Immunotherapy, Adoptive / Q000379:methods*; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology; D008546:Melanoma, Experimental / Q000276:immunology* / Q000473:pathology / Q000517:prevention & control / Q000628:therapy*; D051379:Mice; D013601:T-Lymphocytes / Q000276:immunology